Rheumatoid Arthritis often starts during the prime of a person’s working life, typically between the age of 35 and 45. Women are 3 times more likely to develop the disease than men. It is an incurable, painful and debilitating auto-immune disease where the body attacks itself, most noticeably in the joints. The total direct and indirect cost of RA in the UK is estimated to cost up to £4.75bn per year.
Methotrexate (MTX) is the current drug prescribed for patients with RA in the UK but if this treatment is not working, patients may also be given a biological drug to help control their disease. However, of the estimated 46,000 RA patients on a biological treatment, 1 in 3 are not taking methotrexate, often because they are intolerant to this treatment. The other most widely prescribed drug is Humira.
However a pioneering study has shown fantastic results, among 326 patients, at five trial centres in the UK, which has shown that almost four times as many RA patients achieve complete disease remission taking RoActemra in comparison to Humira for patients who cannot take Methotrexate.
In this video: ← Leading experts in the treatment of Rheumatoid Arthritis provide an outline of the disease is and what the current treatment options are to those living with the condition. The experts go on to explain what the new smart drug RoActermra is and why the latest clinical data is so important.
Either click here or on the photo or the link above to view the video.
All content on Silverhairs.com is provided for general information only, and should not be treated at all as a substitute for the medical advice of your own doctor or any other health care professional. Silverhairs.com will not be responsible or liable for any diagnosis made by a user based on the content on www.silverhairs.com and we are also not liable for the content of any external websites or links from or to Silverhairs to any other websites. Please always consult your own doctor if you’re in any way concerned about any aspect of your health.